Dementia and subthalamic deep brain stimulation in Parkinson disease
A long-term overview
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives To assess the prevalence and the cumulative incidence of dementia at short-, medium- and long-term follow-up after deep brain stimulation (DBS) of the subthalamic nucleus (STN) (at 1, 5, and 10 years) and to evaluate potential risk factors for postoperative dementia.
Methods The presence of dementia (according to the DSM-V) was retrospectively evaluated at each postoperative follow-up in patients with Parkinson disease (PD) who underwent bilateral STN-DBS. Preoperative and perioperative risk factors of developing postoperative dementia were also investigated. Demographic data, disease features, medications, comorbidities, nonmotor symptoms, PD motor scales, neuropsychological scales at baseline, and perioperative complications were collected for each patient.
Results A total of 175 patients were included, and 104 were available at 10-year follow-up. Dementia prevalence was 2.3% at 1 year, 8.5% at 5 years, and 29.8% at 10 years. Dementia cumulative incidence at 1, 5, and 10 years was 2.3%, 10.9%, and 25.7%, respectively. The corresponding dementia incidence rate was 35.6 per 1,000 person-years. Male sex, higher age, hallucinations, lower frontal score at baseline, and perioperative cerebral hemorrhage were predictors of dementia.
Conclusions In patients with PD with longstanding STN-DBS, dementia prevalence and incidence are not higher than those reported in the general PD population. Except for few patients with perioperative cerebral hemorrhage, STN-DBS is cognitively safe, and does not provide dementia risk factors in addition to those reported for PD itself. Identification of dementia predictors in this population may improve patient selection and information concerning the risk of poor cognitive outcome.
Glossary
- CHU=
- Centre Hospitalier Universitaire of Grenoble;
- CI=
- confidence interval;
- DBS=
- deep brain stimulation;
- DSM-V=
- Diagnostic and Statistical Manual of Mental Disorders, 5th edition;
- HR=
- hazard ratio;
- LEDD=
- levodopa equivalent daily dose;
- PD=
- Parkinson disease;
- STN=
- subthalamic nucleus;
- WCST=
- Wisconsin Card Sorting Test
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received September 7, 2019.
- Accepted in final form January 6, 2020.
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Author response: Dementia and subthalamic deep brain stimulation in Parkinson disease: A long-term overview
- Francesco Bove, Neurologist, CHU Grenoble Alpes, Università Cattolica del Sacro Cuore
- Valerie Fraix, Neurologist, CHU Grenoble Alpes
- Francesco Cavallieri, Neurologist, CHU Grenoble Alpes, University of Modena and Reggio Emilia
- Emmanuelle Schmitt, Neuropsychologist, CHU Grenoble Alpes
- Eugénie Lhommée, Neuropsychologist, CHU Grenoble Alpes
- Amélie Bichon, Neuropsychologist, CHU Grenoble Alpes
- Sara Meoni, Neurologist, CHU Grenble Alpes
- Pierre Pélissier, Clinical Research Coordinator, CHU Grenoble Alpes
- Andrea Kistner, Clinical Research Coordinator, CHU Grenoble Alpes
- Eric Chevrier, Physical Therapist, CHU Grenoble Alpes
- Claire Ardouin, Neuropsychologist, CHU Grenoble Alpes
- Patricia Limousin, Neurologist, University College London Queen Square
- Paul Krack, Neurologist, University Hospital Bern
- Alim Louis Benabid, Neurosurgeon, CHU Grenoble Alpes
- Stephan Chabardès, Neurosurgeon, CHU Grenoble Alpes
- Eric Seigneuret, Neurosurgeon, CHU Grenoble Alpes
- Anna Castrioto, Neurologist, CHU Grenoble Alpes
- Elena Moro, Neurologist, CHU Grenoble Alpes
Submitted September 05, 2020 - Reader response: Dementia and subthalamic deep brain stimulation in Parkinson disease: A long-term overview
- Tomoyuki Kawada, Professor, Nippon Medical School
Submitted August 27, 2020
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Suicide and suicide attempts after subthalamic nucleus stimulation in Parkinson diseaseGiulia Giannini, Matthieu Francois, Eugénie Lhommée et al.Neurology, May 17, 2019 -
Views and Reviews
A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PDR.J. St. George, J.G. Nutt, K.J. Burchiel et al.Neurology, October 04, 2010 -
Articles
Randomized trial of deep brain stimulation for Parkinson diseaseThirty-six-month outcomesFrances M. Weaver, Kenneth A. Follett, Matthew Stern et al.Neurology, June 20, 2012 -
Articles
Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson diseaseA. Sailer, D. I. Cunic, G. O. Paradiso et al.Neurology, January 29, 2007